Table 1.
Clinical features of IRIS patients
| Patient | CD4 T cell count before ART cells/μl | CD4 T cell count at presentation of IRIS cells/μl | Fold change in CD4 T cell counts from baseline to IRIS presentation | CD4 T cell count after remission of IRIS cells/μl | HIV-1 RNA at presentation of IRIS copies/ml | Reason for admission | Time on therapy* | Therapy |
| 1 | 7 | 69 | 9.86 | 202 | U/D | MAC | 8 | d4T+ddI+NFV+ImRx |
| 2 | 37 | 70 | 1.89 | 140 | U/D | MAC | 12 | AZT+3TC+IDV+ImRx |
| 3 | 4 | 45 | 11.25 | 93 | U/D | MAC | 18 | d4T+ddI+NFV+ImRx |
| 4 | 90 | 280 | 3.11 | 601 | U/D | MAC | 8 | AZT+3TC+EFV+ImRx |
*Time in months from initiation of potent ART until diagnosis of IRIS. Drugs used in ART regime: Nucleoside analogues; Stavudine (d4T), Didanosine (ddI), Lamivudine (3TC) and Zidovudine (AZT) Protease inhibitors; Nelfinavir (NFV), Indinavir (IDV), or Non-nucleoside reverse transcriptase inhibitor; Efavirenz (EFV); ImRx = immunotherapy; MAC = Mycobacterium avium complex.